Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT MESO intraperitoneal paclitaxel study in malignant peritoneal mesothelioma
NL-OMON26729Phase 2Not yet recruiting
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in peritoneal mesothelioma, sponsored by None. Primary endpoint: Maximum tolerated dose of intraperitoneal paclitaxel. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NL-OMON26729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26729.